MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l [m] n o p q r s t u v w x y z
  • Machine learning classifiers and subjective vocal perception of Parkinson’s disease patients and healthy control

    Y. Manor, S. Naor, D. Shpunt, N. Diamant, A. Hillel, A. Ezra, I. Opher, Y. Hauptman, R. Aloni-Lavi, A. Faust-Socher, H. Shabtai, R. Peled, A. Migirov, T. Gurevich (Tel Aviv, Israel)

  • Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 Study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)

    B. Leavitt, R. Reilmann, M. Gordon, K. Anderson, A. Feigin, S. Tabrizi, J. Stout, P. Piccini, B. Russell-Schulz, A. Mackay, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Vancouver, BC, Canada)

  • Maladaptive Nigrovagal Neuronal Plasticity Causes Ascending Alpha-Synucleinopathy in a Novel Environmental Toxin Based Rat Model of Parkinsonism

    T. Subramanian, K. Le, S. Hojjatinia, K. Venkiteswaran, M. Subramanian, L. Anselmi, C. Bove, R. Travagli (Hershey, PA, USA)

  • Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection

    F. Rakhimov, B. Sultanov (Tashkent, Uzbekistan)

  • Management of life threatening dyskinesias in GNAO1 related movement disorder: two new cases and review of the literature

    M. Hull, M. Parnes (Houston, TX, USA)

  • Management of Patients with Functional Movement Disorders: A Transcultural Perspective

    C. Maurer, D. Anderson, A. Asadi-Pooya, J. Baizabal, M. Damianova, C. Ganos, R. Kanaan, M. Tijssen, J. Kwasa, I. Moreno, S. Pandey, JE. Park, D. Saylor, M. Stamelou, C. Stephen, T. Teodoro, M. Tinazzi, K. Lafaver (Stony Brook, NY, USA)

  • Management of poor response to Botulinum toxin in cervical dystonia: a multicentre audit

    H. Tucker, F. Osei-Poku, D. Ashton, R. Lally, J. Alty, C. Kobylecki (Salford, United Kingdom)

  • Mandibular Advancement Device in Parkinson’s disease: an efficacious and usable device in a disabling disease

    V. Cochen Decock, M. Castel, I. Bonafé (Montpellier, France)

  • MCI reverters have a favorable cognitive prognosis and cortical integrity in Parkinson’s disease

    SJ. Chung, Y-H. Park, YH. Sohn, J-M. Lee, PH. Lee (Seoul, Republic of Korea)

  • MDS Rare Movement Disorders Study Group Global Genetic Testing Survey: exploring the unmet needs

    R. Walker, H. Jinnah, M. Rodriguez Violante, C. Gonzalez, E. Gatto (New York, NY, USA)

  • MDS Translation Program for MDS-UPDRS and UDysRS

    S. Luo, N. Lapelle, P. Martin, C. Goetz, G. Stebbins (Durham, NC, USA)

  • MDS-UPDRS Part III predictors of Part II Item Scores in PPMI

    J. Cedarbaum, Z. Xiao, M. Yang (Cambridge, MA, USA)

  • Measurement properties of the MDS-NMS Non-motor Fluctuations Subscale

    MJ. Forjaz, A. Ayala, C. Rodriguez-Blazquez, A. Schrag, D. Weintraub, A. Rizos, KR. Chaudhuri, P. Martinez-Martin (Philadelphia, PA, USA)

  • Measuring cognitive decline in PD-MCI patients with high level education: Do we have the appropriate tools?

    L. Mentzer, A. Richardson, T. Nevo, S. Meyer, S. Rosenblum, N. Gemerman, S. Hassin-Baer, S. Israeli-Korn, T. Fay-Karmon, V. Livneh, G. Yahalom (Ramat-Gan, Israel)

  • Measuring disease progression with neuroimaging in MSA-a systematic review

    B. Heim, F. Krismer, W. Poewe, K. Seppi (Innsbruck, Austria)

  • Measuring perceived-health status in Parkinson’s Disease – the role of London Handicap Scale

    D. Silva, M. Coelho, T. Soares, T. Vale, L. Guedes, R. Maciel, A. Antunes, S. Camargos, A. Valadas, C. Godinho, D. Maia, P. Lobo, R. Maia, T. Teodoro, C. Rieder, A. Velon, M. Rosas, A. Calado, V. Caniça, F. Cardoso, J. Ferreira (Lisbon, Portugal)

  • Measuring progression of nigrostriatal degeneration in Parkinson’s disease using 18F-AV-133 vesicular monoamine transporter type-2 (VMAT2) PET

    S. Xu, V. Dore, P. Alexander, Y. Lie, S. Bozinovski, R. Mulligan, K. Young, V. Villemagne, C. Rowe (Melbourne, Australia)

  • Mechanism-based classification in PD cohorts

    B. Labrador, F. Danjou, S. Bekadar, FX. Lejeune, H. Froehlich, M. Hofmann-Apitius, JC. Corvol (Paris, France)

  • Mechanisms underlying therapeutic group singing in persons with Parkinson’s disease

    E. Stegemoller, A. Zaman, K. Diaz, E. Shirtcliff, M. Kohut (Ames, IA, USA)

  • Medical and Device-Guided Therapies and Deep Brain Stimulation in Parkinson’s disease: Experience of a Tertiary Centre from Turkey

    Y. Sucullu Karadag, D. Divanlıoglu, E. Kocabicak, N. Subutay Oztekin, D. Belen (Ankara, Turkey)

  • Medical evaluation as gold standard to control iPrognosis application derived data for early Parkinson’s disease detection

    L. Klingelhoefer, S. Bostanjopoulou, D. Trivedi, S. Hadjidimitriou, S. Mayer, Z. Katsarou, V. Charisis, M. Stadtschnitzer, S. Dias, G. Ntakakis, N. Grammalidis, K. Kyritsis, H. Jaeger, D. Iakovakis, I. Ioakeimidis, F. Karayiannis, J. Diniz, A. Delopoulos, L. Hadjileontiadis, H. Reichmann, K. Chaudhuri (Dresden, Germany)

  • Medical management after subthalamic nucleus deep brain stimulation in patients with Parkinson’s Disease

    A. Bertholo, R. Cury (São Paulo, Brazil)

  • Medical management of primary hemifacial spasm

    G. Kumar, D. Kaur, A. Singh (Patna, India)

  • Memantine and 3D gait analysis in patient with Parkinson’s disease: an observer-blind randomized clinical trial

    I. Miliukhina, E. Gracheva (Saint-Petersburg, Russian Federation)

  • Memantine induced dyskinesia in Alzheimer’s disease

    M. Kaiserova, L. Hvizdošova, K. Mensikova, P. Kanovsky (Olomouc, Czech Republic)

  • Memory enhancing effect of Combined Alcoholic Extract of Cedrus deodara Loud. and Vitex Nirgundi in scopolamine-induced cognitive impairment in mice

    A. Jain, S. Jain (Sagar, India)

  • MEMs-based Measurement and Classification System of Tremors in Parkinson Disease using MDS-UPDRS Scale as a Parameter

    A. Delatorre, J. Marques (Florianópolis, Brazil)

  • Metabolic network abnormalities in drug-naive Parkinson’s disease

    O. Lucas-Jimenez, K. Schindlbeck, C. Tang, S. Morbelli, D. Arnaldi, M. Pardini, M. Pagani, F. Nobili, D. Eidelberg (Bilbao, Spain)

  • Metabolic Surgery in the adjuvant management of Parkinson’s Disease

    C. Jauregui Pasache, W. Kunz Martínez, A. Pérez Pacheco (Querétaro, Mexico)

  • Metabolic syndrome and insulin resistance in Parkinson’s disease: could they affect motor or cognitive symptoms?

    M. Hussein, A. Khamis, R. Soliman, S. Ali (Beni Suef, Egypt)

  • Metabolomic Analysis of Fecal Matter from Parkinsonian Mice

    V. Vedam-Mai, E. Gill, J. Koelmel, R. Yost, T. Garrett, M. Okun (Gainesville, FL, USA)

  • Methylation status of SNCA gene in patients with Parkinson disease in Russian population

    E. Iakovenko, N. Abramycheva, S. Illarioshkin, E. Fedotova (Moscow, Russian Federation)

  • MIBG myocardial scintigraphy identifies premotor PD/DLB during a negative DAT scan period

    R. Sakakibara, F. Tateno, Y. Aiba (Sakura, Japan)

  • Micro structural Changes in Substantia Nigra are associated with Severity of Parkinson’s Disease.

    A. Safai, S. Rane, S. Prasad, J. Saini, P. Pal, M. Ingalhalikar (Pune, India)

  • Microglia as modulators of exosomal alpha-synuclein transmission

    Y. Xia, T. Wang, GX. Zhang, JS. Huang, N. Xiong, L. Liu, F. Wan, L. Kou, SJ. Yin, JJ. Hu, YD. Sun, JW. Wu (Wuhan, China)

  • MicroRNA Expression in the Diagnosis of Parkinson’s Disease

    J. Roy, D. Guévremont, A. Garvey, N. Cutfield, J. Williams (Dunedin, New Zealand)

  • Microstructural Changes in Basal Ganglia and Cerebellar Networks in Patients with Idiopathic Blepharospasm

    M. Esposito, T. Yousaf, H. Wilson, S. Peluso, L. Santoro, F. Manganelli, G. Pagano, M. Politis (Naples, Italy)

  • Midbrain Atrophy in Patients with Preclinical Progressive Supranuclear Palsy

    JH. Ahn, M. Kim, J. Youn, JS. Kim, JK. Mun, PH. Lee, SB. Koh, TB. Ahn, JW. Cho (Seoul, Republic of Korea)

  • Mild Cognitive Impairment in Parkinson’s disease in South Indian population – Development of a test battery and assessment of prevalence and characteristics

    S. Krishnan Nair, R. Ramesh, G. Sarma, D. Puthenveedu, R. Menon, A. Kishore (Thiruvananthapuram, India)

  • Mild Cognitive Impairment in Young Onset Parkinson Disease

    A. Troster, C. Schweer (Phoenix, AZ, USA)

  • Mindfulness Based Stress Reduction in People with Parkinson’s Disease and their Carepartners

    D. Shah, S. Mantri, J. Cooney, A. Allen, K. Durham, J. Brantley, R. Vereen, P. Hickey, B. Scott (Durham, NC, USA)

  • Mindfulness Training to Reduce Anxiety in Parkinson’s Disease: A Cautionary Tale about Wearable Technology

    D. Mohanty, A. Lingaiah, J. Doak, A. Jacob, R. Castellanos, V. Holiday, A. Espay, K. Lafaver (Louisville, KY, USA)

  • Misdiagnosis in blepharospasm: the common imitators which should not be missed

    S. Desai, S. Thati, D. Desai (Anand, India)

  • Mitigation Effects of a Novel Herbal Medicine Hepad, on neurophysiology.

    BJ. Park, DH. Kim, JM. Park (Daejeon, Republic of Korea)

  • Mitochondrial Complex 1, Sigma 1 Receptor and Synaptic Vesicle protein 2A density in early de novo patients with Parkinson’s Disease: pilot PET data

    G. Pagano, H. Wilson, A. Mansur, S. Caminiti, R. Comley, H. Tsukada, R. Gunn, E. Rabiner, M. Politis (London, United Kingdom)

  • Moaning: genetic analysis of a family with eight affected members

    M. Rossi, M. Gisatulin, C. Perandones, C. Klein, M. Merello, K. Lohmann (Buenos Aires, Argentina)

  • Mobility Impairments in Huntington’s Disease due to Cognitive Dysfunction

    M. Rakhimova, N. Yusupova (Tashkent, Uzbekistan)

  • Modeling of Parkinson’s disease by damaging dopaminergic neurons

    L. Toshpulatova, M. Kulmanova (Tashkent, Uzbekistan)

  • Modeling the Effect of Patient’s Perception of Non-Motor and Motor Function on Parkinson’s Disease Severity

    C. Goetz, S. Luo, G. Stebbins (Chicago, IL, USA)

  • Modern aspects of genetics of child cerebral palsy with symptomatic epilepsy

    D. Aminova (Tashkent, Uzbekistan)

  • Modifiable factors and progression of motor symptoms and cognitive decline in Parkinson’s disease

    E. Forbes, T. Tropea, S. Mantri, J. Morley (Philadelphia, PA, USA)

  • Modulation of cerebellar and basal ganglia loops affects vestibular processing in Parkinson’s disease

    J. Liao, C. Mcintyre, A. Shaikh (Cleveland, OH, USA)

  • Modulation of Na+/K+ ATPase activity of rat brain synaptosome by norepinepherine and serotonin

    S. Sinha (Prayagraj, India)

  • Modulation of the Startle Response in REM Sleep Behavior Disorder

    M. Puligheddu, M. Figorilli, ML. Fantini, M. Carta, F. Traccis, R. Frau, P. Devoto, D. Pani, M. Bortolato (Salt Lake City, UT, USA)

  • Molecular correlates of survival and clinical severity in Progressive Supranuclear Palsy

    M. Malpetti, L. Passamonti, T. Rittman, P. Vázquez Rodríguez, W R. Bevan-Jones, F I. Aigbirhio, J T. O'Brien, J B. Rowe (Cambridge, United Kingdom)

  • Molecular Integration in Neurological Diagnosis (MIND): A Center-Wide Approach to Improve Molecular and Genetic Characterization of Parkinson’s Disease

    T. Tropea, J. Rick, N. Han, S. Rudovsky, A. Siderowf, V. van Deerlin, A. Chen-Plotkin (Philadelphia, PA, USA)

  • Monitoring Parkinson’s disease symptoms during daily life: A feasibility study

    M. Heijmans, J. Habets, C. Herff, M. Kuijf, P. Kubben (Maastricht, Netherlands)

  • Motor and Non-Motor Symptom Burden in Parkinsonian and Cerebellar Phenotypes of Probable MSA

    M R. Rukmani, R. Yadav, P K. Pal, B. Bhaskarapillai, T N. Sathyaprabha (Bangalore, India)

  • Motor and non-motor symptoms burden, autonomy, quality of life and principal caregiver status is worse in patients with 5-2-1 positive criteria: a simple screening tool for identifying PD patients who need an optimization of Parkinson´s treatment.

    D. Santos, T. de Deus, E. Suárez Castro, A. Aneiros (A Coruña, Spain)

  • Motor and non-motor symptoms differences between Vascular Parkinsonism (VP) and Parkinson’s Disease (PD) patients in early stages

    R. Raimundo, M. Mendes, R. Jesus, C. Azoia, A. Almeida, AG. Velon (Vila Real, Portugal)

  • Motor and non-motor symptoms in the prediagnostic phase of progressive supranuclear palsy: the Step-Back PSP study.

    C. Painous, C. Simonet, A. Garrido, N. Caballol, M. Guasp, A. Cámara, F. Valldeoriola, JE. Muñoz, MJ. Martí, Y. Compta (Barcelona, Catalonia)

  • Motor and non-motor symptoms related to sleep disturbances in Parkinson’s disease

    D. van Wamelen, V. Leta, A. Podlewska, Y. Wan, A. Sauerbier, A. Rizos, P. Martinez-Martin, K. Chaudhuri (Madrid, Spain)

  • Motor assessments in HD clinical trials: Q-Motor versus the UHDRS-TMS – what did we learn from recent studies?

    R. Reilmann, R. Schubert, P. Barallon, P. Pracht, B. Habbel (Muenster, Germany)

  • Motor compensation in Parkinson’s disease: a multimodal neuroimaging study

    N. Villain, N. Pyatigorskaya, S. Lehericy, R. Vallabregue, S. Fernandez-Vidal, MO. Habert, G. Mangone, JC. Corvol, M. Vidailhet, D. Grabli (Paris, France)

  • Motor intracortical excitability before speech onset in adults who stutter

    A. Elfers, S. Hommel, N. Neef, AW. von Gudenberg, W. Paulus, M. Sommer (Bad Emstal, Germany)

  • Motor learning and long duration response to levodopa in Parkinson’s disease.

    G. Sciacca, G. Mostile, I. Disilvestro, G. Donzuso, R. Manna, G. Portaro, C. Rascunà, S. Salomone, F. Drago, A. Nicoletti, M. Zappia (Catania, Italy)

  • Motor Networks in Tremor-Dominant Parkinson’s Disease. A resting-state functional MRI and diffusion tensor imaging analysis.

    Z. Chappell, H. Wilson, M. Politis (London, United Kingdom)

  • Motor Response Inhibition – A potential tool to determine optimum STN-DBS setting

    H. Kumar, A. Roy, S. Choudhury, P. Basu, M. Baker, S. Baker (Kolkata, India)

  • Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study

    J. Hui, S. Fox, W. Neeson, P. Bhargava, E. Pappert, D. Blum, B. Navia (Los Angeles, CA, USA)

  • Motor Symptoms in Typical Brain Aging

    J. Zitser, K. Casaletto, A. Staffaroni, C. Sexton, A. Wolf, J. Brown, B. Miller, J. Kramer (San Francisco, CA, USA)

  • Motor Training Based on Video Games Reduces Freezing of Gait Regardless of Games Combination: A Parallel, Prospective, Double-Blind, Randomized Clinical Trial

    P. Barbosa, A. Lopes, A. Falconi, M. D’Alencar, M. Piemonte (Sao Paulo, Brazil)

  • Motor-based assessment of prodromal Parkinson’s disease combining wearable sensors and machine learning

    E. Rovini, A. Moschetti, L. Fiorini, D. Esposito, C. Maremmani, F. Cavallo (Pontedera, Italy)

  • Movement and symptom-modulated local field potentials in globus pallidus internus of Parkinson’s disease

    J. Aman, L. Johnson, D. Sanabria, J. Wang, M. Hill, S. Cooper, L. Schrock, M. Petrucci, G. Molnar, C. Mackinnon, R. Patriat, N. Harel, M. Park, J. Vitek (Minneapolis, MN, USA)

  • Movement disorders as a clinical feature of Subacute Sclerosing Pan Encephalitis: Expansion of phenotypic spectrum

    D. Dash, M. Tripathi, R. Singh (Delhi, India)

  • Movement disorders associated with autoimmune encephalitis

    A. Chouksey, S. Pandey (New Delhi, India)

  • Movement disorders associated with intracranial and extracranial artery diseases

    N. Choi, KW. Park, S. Jo, SJ. Chung (Seoul, Republic of Korea)

  • MOVEMENT DISORDERS FEATURES ASSOCIATED WITH WEST SYNDROME

    FS. Ngoungoure Halima, AM. Magnerou, CV. Hotcho Nganhou, M. Ndiaye, AG. Diop (Douala, Cameroon)

  • Movement disorders in chronic obstructive pulmonary disease (COPD); the effect of pulmonary disease to brain

    K. Methawasin, R. Suppawat, P. Petborom, M. Wongwandee, S. Rungruanghiranya, T. Asawavichienjinda (Ongkharak, Thailand)

  • Movement disorders in late-onset inborn errors of metabolism – a new diagnostic algorithm

    L.. Koens, M. Tijssen, T. de Koning (Groningen, Netherlands)

  • Movement disorders in neurologic consultation of Marrakesh University Hospital

    L. Berrhoute, J. El Mesbahy, N. Kissani (Marrakesh, Morocco)

  • Movement Disorders in Post Stroke Patients: A Retrospective Analysis

    M. Christie, V. Laticevschi, R. Mehanna (Houston, TX, USA)

  • Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment

    B. Kennedy, J. Peterson, D. Charles (Washington, DC, USA)

  • Movement Disorders Spectrum in a Private Practice setup in India : A 7 Year Study

    P. Kukkle (Bangalore, India)

  • Movement disorders spectrum in patients with frontotemporal dementia

    YU. Shpilyukova, E. Fedotova, D. Grishina, S. Illarioshkin (Moscow, Russian Federation)

  • Moving ear syndrome secondary to bromopride and response to botulinum toxin

    F. Sekeff-Sallem, J. Pedroso, O. Barsottini (Sao Paulo, Brazil)

  • MR-guided high intensity focused ultrasound in Parkinson’s disease: A case report with a 5 year follow up

    S. Haegele-Link, N. Wegener, F. Brugger, J. Walch, R. Bauer, E. Martin, B. Werner, D. Brogle, G. Kaegi (St. Gallen, Switzerland)

  • MRI based Volumetric analysis of the sub-thalamic and red nuclei in Advanced Parkinson’s disease- an institutional study

    V. Shah, R. Alugolu, R. Kandadai, A. Arora (Hyderabad, India)

  • MRI cortical layer study in patients with Parkinson’s disease in Uzbekistan

    A. Umarov, D. Tolibov (Tashkent, Uzbekistan)

  • MRI, Clinical, and Neuropathological Findings after Bilateral Intra-striatal Administration of rAAV5-miHTT in Non-human Primates

    J. Higgins, B. Blits, L. Spronck, A. Valles-Sanchez, M. Evers, S. van Deventer, P. Konstantinova, M. de Haan (Lexington, MA, USA)

  • Mu opioid receptor agonism, not antagonism, for the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease

    E. Bezard, Q. Li, E. Pioli, A. Crossman (Bordeaux, France)

  • Multi-kinase Abelson (c-Abl) and Discoidin Domain Receptors (DDR1/2) inhibitors, Nilotinib, alters CSF soluble TREM2 (sTREM2) in individuals with Parkinson’s Disease

    F. Pagan, M. Hebron, B. Wilmarth, Y. Torres-Yaghi, E. Mundel, N. Yusuf, C. Moussa (Washington, DC, USA)

  • Multi-modal MRI in patients with genetically confirmed familial cortical myoclonic tremor with epilepsy type 1

    F. Xie, B. Wang, J. Wang, Z. Cen, W. Wei, Y. Chen, H. Sun, D. Yang, Y. Lou, X. Chen, S. Chen, H. Wang, L. Wang, S. Wang, X. Qiu, Y. Ding, H. Yin, S. Wu, B. Zhang, Y. Zang, W. Luo (Hangzhou, China)

  • Multimodal characterization of the visual network in Huntington’s disease

    O. Odish, S. Gregory, I. Mayer, J.. Mills, E. Johnson, R. Scahill, J. Rothwell, G. Rees, J. Long, S. Tabrizi, R. Roos, M. Orth (Leiden, Netherlands)

  • Multimodal Graph Theory Analysis Identifies Reward Network in Prediction of Motor Response to Deep Brain Stimulation

    J. Muller, L. Li, C. Matias, M. Alizadeh, J. Miao, S. Thalheimer, V. Romo, F. Mohamed, C. Wu (Philadelphia, PA, USA)

  • Multimodal PET and fcMRI reveals regional modulation by STN DBS correlating to motor outcomes

    J. Younce, A. Tanenbaum, M. Campbell, J. Perlmutter, S. Norris (St Louis, MO, USA)

  • Multiple System Atrophy – perspectives in diagnosis?

    P. Alster, D. Koziorowski, L. Królicki, A. Friedman (Warsaw, Poland)

  • Multiple system atrophy with predominant striato-nigral degeneration (MSA-P) and TDP-43 pathology: an unusual pathologic variant of MSA

    L. Nwabuobi, D. Tomishon, N. Shneider, S. Fahn, J. Vonsattel, E. Cortes (New York, NY, USA)

  • Multiple System Atrophy: phenotypic spectrum approach coupled with brain FDG PET

    A. Eusebio, E. Guedj, JP. Azulay, M. Renaud, M. Boucekine, S. Grimaldi (Marseille, France)

  • Muscle Ultrasound Comparison between Early, Intermediate and Late Onset Friedreich’s Ataxia

    R. Verbeek, A. Waalkens, M. Kuiper, C. Verschuuren-Bemelmans, J. Vd Hoeven, J. de Vries, J. van Gaalen, M. Willemsen, H. Kremer, K. Bürk, D. Sival (Groningen, Netherlands)

  • Musician’s dystonia: results from a large US case series

    C. Stephen, M. Charness (Boston, MA, USA)

  • Musicoterapy and Neurorehabilitation in Patients with Parkinson’s Disease

    TR. Alcântara-Silva, DJS. Silva, AL. Alcântara-Silva, S. Suzuki-Godoy (Goiânia, Brazil)

  • Myoclonus-Dystonia Syndrome Due to a Novel Mutation in the Epsilon-Sarcoglycan (SGCE) Gene

    C. Gonzalez Robles, A. Rojo Sebastian, J. Garcia Diaz (Alcala de Henares, Spain)

  • Myokymia and Tremor-like Involuntary Movement in A Patient with Chronic Inflammatory Demyelinating Polyradiculoneuropathy

    CH. Tsai, Y. Aoh, YC. Guo, MK. Lu (Taichung, Taiwan)

  • MYORG is associated with recessive primary familial brain calcification

    D. Arkadir, A. Lossos, D. Rahat, M. Abu Snineh, V. Meiner (Jerusalem, Israel)

Jump to:  View All • a b c d e f g h i j k l [m] n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley